85 related articles for article (PubMed ID: 16963728)
21. Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas.
Fraile JM; Ordóñez GR; Quirós PM; Astudillo A; Galván JA; Colomer D; López-Otín C; Freije JM; Puente XS
Oncotarget; 2013 Nov; 4(11):1919-32. PubMed ID: 24243807
[TBL] [Abstract][Full Text] [Related]
22. Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor.
Kong PZ; Yang F; Li L; Li XQ; Feng YM
PLoS One; 2013; 8(4):e61591. PubMed ID: 23620774
[TBL] [Abstract][Full Text] [Related]
23. Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.
Kotoula V; Kalogeras KT; Kouvatseas G; Televantou D; Kronenwett R; Wirtz RM; Fountzilas G
Virchows Arch; 2013 Feb; 462(2):141-54. PubMed ID: 23262785
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling of individual tumor cells by hyperspectral microscopic imaging.
Uhr JW; Huebschman ML; Frenkel EP; Lane NL; Ashfaq R; Liu H; Rana DR; Cheng L; Lin AT; Hughes GA; Zhang XJ; Garner HR
Transl Res; 2012 May; 159(5):366-75. PubMed ID: 22500509
[TBL] [Abstract][Full Text] [Related]
25. Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
Kotzsch M; Magdolen V; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Eckert AW; Luther T; Baretton G; Würl P; Taubert H
BMC Cancer; 2011 Jun; 11():273. PubMed ID: 21702998
[TBL] [Abstract][Full Text] [Related]
26. GOBO: gene expression-based outcome for breast cancer online.
Ringnér M; Fredlund E; Häkkinen J; Borg Å; Staaf J
PLoS One; 2011 Mar; 6(3):e17911. PubMed ID: 21445301
[TBL] [Abstract][Full Text] [Related]
27. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.
Foekens JA; Sieuwerts AM; Smid M; Look MP; de Weerd V; Boersma AW; Klijn JG; Wiemer EA; Martens JW
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13021-6. PubMed ID: 18755890
[TBL] [Abstract][Full Text] [Related]
28. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
Wang XD; Reeves K; Luo FR; Xu LA; Lee F; Clark E; Huang F
Genome Biol; 2007; 8(11):R255. PubMed ID: 18047674
[TBL] [Abstract][Full Text] [Related]
29. Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome.
Vuaroqueaux V; Urban P; Labuhn M; Delorenzi M; Wirapati P; Benz CC; Flury R; Dieterich H; Spyratos F; Eppenberger U; Eppenberger-Castori S
Breast Cancer Res; 2007; 9(3):R33. PubMed ID: 17535433
[TBL] [Abstract][Full Text] [Related]
30. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?
Cristofanilli M; Mendelsohn J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17073-4. PubMed ID: 17090687
[No Abstract] [Full Text] [Related]
32. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.
Meng S; Tripathy D; Shete S; Ashfaq R; Saboorian H; Haley B; Frenkel E; Euhus D; Leitch M; Osborne C; Clifford E; Perkins S; Beitsch P; Khan A; Morrison L; Herlyn D; Terstappen LW; Lane N; Wang J; Uhr J
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17361-5. PubMed ID: 17079488
[TBL] [Abstract][Full Text] [Related]
33. Comparison of gene expression profiles in core biopsies and corresponding surgical breast cancer samples.
Zanetti-Dällenbach R; Vuaroqueaux V; Wight E; Labuhn M; Singer G; Urban P; Eppenberger U; Holzgreve W; Eppenberger-Castori S
Breast Cancer Res; 2006; 8(4):R51. PubMed ID: 16919157
[TBL] [Abstract][Full Text] [Related]
34. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
[TBL] [Abstract][Full Text] [Related]
36. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
37. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
38. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Duffy MJ
Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
